LOGIN
Rivaroxaban Superior to Enoxaparin in Non-Major Orthopaedic Surgery for Prevention of Major VTE
July 2020
Rivaroxaban Superior to Enoxaparin in Non-Major Orthopaedic Surgery for Prevention of Major VTE
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
N Engl J Med. 2020 May 14;382(20):1916-1925.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Three thousand six hundred and four patients scheduled for a non-major lower limb surgery were randomized to receive oral rivaroxaban or subcutaneous enoxaparin for the prevention of major venous thromboembolic events. The primary outcome of interest was major venous thromboembolism, which was a composite of the incidence of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism a...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.